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Is Myocardial Perfusion Imaging an
Important Predictor of Mortality in Women
And if So, Is This Likely Cost Effective?*
William E. Boden, MD
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fAmong the most common diagnostic tests per-
formed in adults who present with chest pain
symptoms is a noninvasive evaluation of suspected
obstructive coronary artery disease (CAD), which is
performed annually in nearly 20 million patients
(1). The options for testing include the use of the
standard exercise treadmill test (ETT), or the use of
ETT combined with single-photon emission com-
puted tomography (SPECT) myocardial perfusion
imaging (MPI) or, in patients unable to exercise,
the use of MPI with pharmacological vasodilator
stress. Despite the widespread clinical use of ETT,
there is a paucity of randomized trials comparing
See page 880
the effectiveness of the standard ETT with that of
an imaging-guided strategy as an initial diagnostic
strategy and for assessing clinical outcomes of
symptomatic women (1). Current evidence-based
clinical practice guidelines recommend an ETT as
the preferred procedure for the initial evaluation of
women with suspected myocardial ischemia (2).
Yet, frequent reports detail significant limitations in
the accuracy of the electrocardiogram in women,
including a high false-positive rate and the inability
to accurately quantify high lateral or posterolateral
ischemia on the ETT (2). As a result, current
practice patterns are variable and often include
direct referrals of women to higher-cost procedures,
such as exercise MPI.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the University at Buffalo Schools of Medicine and Public Health,a
Buffalo, New York. Dr. Boden has reported that he has no relationships
relevant to the contents of this paper to disclose.It is generally well recognized that physicians
requently underestimate ischemic heart disease
IHD) in women, despite the fact that women with
HD have more adverse outcomes as compared
ith men (3,4). It is also noteworthy to emphasize
hat women represent only 30% of patients enrolled
n clinical trials that form the evidence base used to
upport the 2007 American Heart Association
uidelines for cardiovascular disease prevention in
omen. Even more challenging is the recognition
hat IHD is the most common cause of death
orldwide among adult women, and that data
erived from the World Health Organization
stimates that 80% of IHD deaths occur in
eveloping nations (5). Such observations raise
egitimate concerns regarding the availability and
hoice of various diagnostic approaches that
ould be best deployed to address the growing
roblem of IHD worldwide and, in particular, in
omen with suspected CAD.
Against this backdrop, Cerci et al. (6) report in
his issue of iJACC that in their single-site study
rom the Quanta Nuclear Diagnostic Clinic in
uritiba, Brazil, SPECT-MPI added significant
ncremental prognostic information to clinical and
eft ventricular functional variables while enhancing
he ability to classify this population of Brazilian
omen into low- and high-risk categories of all-
ause mortality. This was an ambitious undertaking
y the Brazilian investigators who, between March
004 and October 2007, studied 2,427 consecutive
emale patients age 55 to 75 years who underwent
PECT-MPI for evaluation of chest pain and
uspected CAD, surveillance of known IHD, inves-
igation of left ventricular (LV) systolic dysfunction,
ollow-up nuclear cardiac imaging for initially
mbiguous or inconclusive treadmill exercise test-
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890ing, or for additional diagnostic evaluation for
diabetes mellitus or pre-operative assessment of
suspected myocardial ischemia. A total of 202
women (8.3% of the observational cohort) had
missing or incomplete follow-up data, and were
excluded from the analysis, leaving a study pop-
ulation of 2,225 women who underwent SPECT-
MPI and in whom mortality, as the primary
outcome measure, was subsequently evaluated
during a mean 3.7-year follow-up.
There are notable strengths of this paper, for
which the authors should be commended. The
current report details the prognostic accuracy of
myocardial perfusion SPECT-MPI in a relatively
large cohort of women referred clinically for nuclear
cardiac noninvasive testing in Brazil. Their study
deals with 2 important populations of patients (i.e.,
women with suspected IHD and subjects from a
developing country) that have been relatively under-
represented in clinical trials, and hence understudied
scientifically as relating to the role of MPI in the
diagnosis and management of IHD. The strengths of
this analysis are the prospective nature of patient
enrollment and data collection as well as the relatively
long length of follow-up (mean: 3.7 years) and appre-
ciable event rate (6.2% cumulative all-cause mortality),
which was the primary outcome measure.
The main study findings appear consistent with
prior published results in the United States and
Europe and provide validation of prior findings to
non-U.S. cohorts. As such, the main study findings
can be considered largely confirmatory of the
known clinical benefits associated with SPECT-
MPI as a prognostic tool among those patients who
exhibit an abnormal scan. In this single-site obser-
vational study, the death rate in Brazilian women
with an abnormal MPI scan was 13.1% as compared
with 4.0% in those with a normal scan (p  0.001).
Further subgrouping of abnormal MPI studies as
“reversible” (mild/moderate vs. severe; complete vs.
partial) and “fixed defects only” revealed differential
survival rates that decreased from 89.8% to 80.3%
and 78.8% in the reversible subgroups, respectively,
as compared with 81% in the “fixed defects” sub-
group. After adjustment for age, risk factors for
ischemic heart disease, and left ventricular ejection
fraction (LVEF), the stepwise multivariable model
showed that the presence of any perfusion defect
(summed stress score  4) was an independent
predictor of mortality. Additionally, when a Cox
proportional hazards analysis was employed, the
authors were able to demonstrate that, after adjust-
ing for known IHD, age, smoking, and LVEF, cSPECT-MPI significantly improved the model
discrimination (or the integrated discrimination
index  0.009; p  0.02), added incremental
rognostic information with an increase in global
hi-square from 87.7 to 127.1; p  0.0001, as well
s improved overall risk prediction (net reclassifica-
ion improvement  0.12; p  0.005. On the
urface, these appear to be impressive findings of
ncremental clinical benefit for SPECT-MPI in the
ohort of Brazilian women studied.
However, there are several limitations of the
resent study that warrant comment. First, because
his was a single-site observational study, there are
bvious concerns that both selection/sampling bias
nd ascertainment bias were important factors in
he results the authors report. Second, there are
ethodological concerns pertaining to SPECT-
PI data acquisition and interpretation; no atten-
ation correction or scatter correction was em-
loyed, and final results of scans were interpreted by
consensus of 2 experienced nuclear cardiology
eaders as opposed to blinded interpretations of
ndependent experts to resolve MPI discrepancies,
hich could have influenced the study findings.
hird, the results of the study were restricted to
razilian women aged 55 to 75 years, so it is unclear
hether the results of the current findings can be
eneralized to younger or older women. In fact, the
uthors never clarify why women younger than age
5 years or older than age 75 years were excluded.
ourth, a sizeable percentage of patients (n  202;
.3%) were lost to follow-up and, despite a post hoc
ensitivity analysis, one cannot be certain to what
egree this—among other unmeasured factors—
ntroduced significant confounding to the current
ndings. Fifth, a large percentage of the study
ohort were asymptomatic (45%), and had pre-
erved systolic function, with a mean LVEF of
4  11%, where only 20% had a history of known
HD. This, again, raises concerns about the validity
nd external generalizability of the study findings to
he larger universe of patients (women or men;
eveloped or undeveloped nations) with suspected
HD for whom physicians would contemplate di-
gnostic testing with SPECT-MPI.
In particular, if we examine the entire study
opulation (n  2,427) of those who underwent
PECT-MPI, less than one-quarter (n  548;
2.6%) had an abnormal scan, of which 443 (81% of
he abnormal group) had a completely reversible
erfusion defect. Importantly, however, in terms of
he severity of the ischemic defect, 382 of 443
ompletely reversible scans (86%) exhibited a mild/
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891moderate defect. Thus, 382 of 2,427 patients
(15.7%) had a mild/moderate defect, and only 166
patients (6.8%) had either a severe reversible perfu-
sion defect (n  61), a fixed perfusion defect (n 
53), or a partial reversible perfusion defect (n 52).
In more closely examining the 3-year risk prediction
models of the incremental utility of adding LVEF
to that of clinical risk, and the SPECT-MPI
perfusion model added to the clinical risk  LVEF
model (Table 3 in Cerci et al. [6]), we see that for
those with a 3-year risk of 3% (37% of all
patients), there is no incremental benefit of either
LVEF or the perfusion models over and above the
clinical model, whereas we see the greatest incre-
mental benefit of the addition of SPECT-MPI in
the subsets of patients with 3% to 6% and 6%
3-year risk of all-cause mortality, as would be
expected.
Event-free survival at a mean 3.7 years was 96%
in the75% of patients with a normal scan (1.1%
annualized mortality), whereas event-free survival
was 90% in the 16% with a mild/moderate
reversible perfusion defect (2.8% annualized mor-
tality), which comprised only about 16% of the
entire cohort. The clearest and most significant
incremental benefit associated with the addition of
SPECT-MPI to either the clinical or clinical 
LVEF model could be demonstrated in the 3 small
subsets of patients (n  166 patients) with either a
severe reversible perfusion defect, a partial reversible
perfusion defect, or a fixed perfusion defect—yet
this comprised only 7% of the entire population.
Thus, although there clearly is incremental benefit
associated with SPECT-MPI in assessing adverse
outcomes, it would appear from these data in Brazilian
women that MPI defines a serious signal of mortality
risk only in a small minority of patients. This raises the
important consideration as to whether, for population
screening purposes, the added complexity, capital
acquisition costs of imaging hardware, and associated
recurring expenditures (e.g., ongoing costs associated
with personnel, software, institutional overhead, etc.)
associated with SPECT-MPI warrant this as a first-
line approach to the detection of IHD and assessing
prognosis.
Clearly, a compelling need exists for higher levels
of scientific evidence, including more randomized
trials, in the area of diagnostic testing and has
resulted in increased attention toward developing
targeted, prospective comparative effectiveness re-
search to more rigorously address the outpatient
diagnostic evaluation of patients with suspected
CAD (1,3). For developing countries such as Braziland many other emerging nations, one has to
confront the more fundamental question of what is
the preferred noninvasive diagnostic test to under-
take in patients with suspected IHD, those with
multiple cardiac risk factors for premature CAD,
those with myocardial systolic dysfunction, or those
who require pre-operative risk stratification or screen-
ing for occult CAD—regardless of gender. This
would seem to be an even more compelling concern in
developing societies such as Brazil where one might
expect that economic constraints and resource utiliza-
tion would be important factors in determining what
diagnostic approaches for detecting suspected IHD in
women, as well as men, are the most clinically appro-
priate and cost effective (7,8).
In the paper by Cerci et al. (6), we cannot discern
whether MPI added significant, incremental diag-
nostic utility over and above standard ETT. The
stress testing method employed for the SPECT-
MPI studies was treadmill exercise testing in 1,626
women (73.1%), pharmacological vasodilator stress
in 567 women (25.6%), and low-level treadmill
exercise combined with pharmacological stress in
only 1.4% of patients. Unfortunately, the authors
provide no data regarding electrocardiographic
findings or Duke Treadmill Score among the al-
most three-quarters of patients who underwent
ETT. One might expect this to be an important
consideration, since standard ETT is far more
prevalent diagnostically, is less costly, and would
logically be expected to be the preferred initial
diagnostic approach to evaluate women and men
with suspected IHD—regardless of whether this
clinical decision by physicians is contemplated in
developed, or developing, nations.
As noted in the preceding text, the evaluation of
women with suspected CAD remains a conundrum
due to their atypical symptom presentation that
often results in varied diagnostic practice patterns.
A recent study, known as the WOMEN (What Is
the Optimal Method for Ischemia Evaluation in
Women) trial, was designed to evaluate whether a
diagnostic strategy using ETT versus exercise MPI
in women with an intermediate pre-test likelihood
of CAD affects 2-year post-test outcomes for major
adverse cardiovascular events (9). In this trial, a
total of 824 women from 43 centers were random-
ized to either standard ETT or ETT  MPI; 88%
of enrolled patients were classified as low-
intermediate risk. For women randomized to ETT
alone, test results were normal in 64.1%, equivocal
in 15.8%, and abnormal in 20.2%. By comparison,
the exercise MPI results were normal in 90.5%,
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892mildly abnormal in 3.3%, and moderate to severely
abnormal in 6.2% of women. At 2 years, there was
no difference in major adverse cardiovascular events
(98.0% for standard ETT and 97.7% for exercise
MPI, p  0.59) (9).
For women randomized to ETT alone, the rate
of crossover to MPI was 17.7% as compared with
repeat MPI in 9.3% for those who underwent an
initial exercise MPI (p  0.0001). Overall, 6.2% of
omen underwent coronary angiography during
ollow-up. As compared with ETT alone, index
esting costs were higher for the exercise MPI group
p  0.001), whereas downstream procedural costs
were slightly lower (p  0.008). Overall, the cumu-
lative diagnostic cost savings was 48% for the
ETT-alone group as compared with the exercise
MPI group (p  0.001) (9). These findings, quite
omparable to the study population of the Brazilian
ohort, show that in low- to intermediate-risk
omen capable of exercise at baseline, a nonimag-
ng strategy employing standard ETT was as effec-
ive in predicting clinical outcomes and more cost
ffective than a strategy of initial exercise MPI.
hus, the principal finding of the WOMEN trial is
hat there was no incremental benefit for an initial
iagnostic strategy of exercise MPI as compared
ith standard ETT only in symptomatic women
ith suspected CAD and preserved functional ca-
acity who were able to exercise. Additionally, we
ould not demonstrate that there was any incre-
ental prognostic benefit of exercise MPI in pre-
icting clinical outcomes at 2 years as compared
ith an ETT-only strategy.
On the basis of the study by Cerci et al. (6), and
in light of the WOMEN trial findings (9), what
conclusions might be drawn from these studies, and
what are the implications for clinical practice? First,
the Brazilian investigators have demonstrated the
incremental value of SPECT-MPI above and be-
yond clinical parameters and LVEF in predicting 3-Clinical Cardiology, and the Cardio- ology of atherosclewith severe reversible, partially reversible, and fixed
perfusion defects. This is an important scientific
contribution. Second, the data derived from the
WOMEN trial suggest that, for women capable of
performing exercise, standard ETT without imag-
ing appears a reasonable (and justifiable) first-line
test resulting in equivalent 2-year outcomes as
compared with ETT  MPI. These results could
ave profound implications for the estimated 2 to 3
illion women undergoing exercise MPI testing
ach year, and would likely result in sizeable cost
avings (i.e., 48%) within the noninvasive diagnos-
ic evaluations for suspected myocardial ischemia
hich, in turn, would lead to reductions in the
ocietal economic burden of medical imaging. Cur-
ent clinical practice patterns often rely on direct
maging strategies for women. In fact, use of MPI
as been one of the fastest growing Medicare
rocedures and routinely ranks as one of its most
ostly expenditures (1). The more judicious use of
xercise MPI as a first diagnostic procedure may
ecrease exposure to ionizing radiation for many
omen, particularly those at low risk for CAD
10,11), even though the preponderance of evidence
upports the fact that lifetime attributable risk of
PI is low (12).
In summary, SPECT-MPI remains a valuable
isk assessment and prognostic tool in patients with
HD. Whether this should be the first-line ap-
roach in women with low to intermediate risk
emains unclear. Performing MPI in developing
ations may also result in additional incurred costs
hat, in light of the above information, need to be
ustified in future studies designed prospectively to
easure and quantify cost effectiveness and resource
tilization in subsets of patients with low, interme-
iate, and high risk for IHD.
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